Astellas enters into definitive contract to acquire Ocata Astellas Pharma Inc.

‘We're confident that people will convert innovative science into value for individuals through the creation of brand-new value by combining both companies' features under 'One Astellas,' where Ocata will be going for a key part in Astellas' R&D in ophthalmology and cell therapy.’ Paul Wotton, Ph.D., President and CEO, Ocata said, ‘I am impressed by the vision and dedication of Astellas and believe that with their global assets behind our regenerative platform, patients suffering from debilitating illnesses like AMD and SMD will soon reap the benefits of having access to regenerative medicine.Alvarez found out a subfamily of arrestins that his team named alpha arrestins. In the current study, Fortune Shea in Dr. Alvarez's lab used imaging and biochemical methods to further identify the part alpha arrestins play in cell signaling. He found that alpha arrestins react to receptor binding and recruit enzymes that chemically modify the receptor to initiate aspects of down regulation. These results occur in the initial five minutes following the receptor is normally bound, once frame that beta arrestins are known to have roles in triggering down regulation.